Autism with Epilepsy: A Neuropsychopharmacology Update

Genes (Basel). 2022 Oct 8;13(10):1821. doi: 10.3390/genes13101821.

Abstract

The association between autism spectrum disorders (ASD) and epilepsy has been extensively documented, and the estimated prevalence varies depending upon the selected population and the clinical characteristics. Currently, there are a lack of studies assessing the patient care pathways in ASD, particularly for comorbidity with epilepsy, despite its personal, familial, and economic impacts. Genetic abnormalities are likely implicated in the association of ASD and epilepsy, although they are currently detectable in only a small percentage of patients, and some known genetic and medical conditions are associated with ASD and epilepsy. There is no specificity of seizure type to be expected in children and adolescents with ASD compared with other neurodevelopmental disorders or epileptic syndromes. Treatment options include antiepileptic drugs (AED) and developmentally-based early interventions for ASD. Carbamazepine and lamotrigine are the most used AED, but further studies are needed to more precisely define the most suitable medications for this specific group of children with ASD.

Keywords: autism; child and adolescent; epilepsy; treatment.

MeSH terms

  • Adolescent
  • Anticonvulsants / therapeutic use
  • Autistic Disorder* / drug therapy
  • Autistic Disorder* / genetics
  • Carbamazepine / therapeutic use
  • Child
  • Epilepsy* / drug therapy
  • Epilepsy* / epidemiology
  • Epilepsy* / genetics
  • Humans
  • Lamotrigine / therapeutic use

Substances

  • Anticonvulsants
  • Lamotrigine
  • Carbamazepine

Grants and funding

This research received no external funding.